OFIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
|Joel Greenblatt 26,468 sh (New)|
Paul Tudor Jones 8,329 sh (New)
Chuck Royce 60,000 sh (New)
Arnold Schneider 119,993 sh (+6.32%)
Diamond Hill Capital 391,926 sh (+5.17%)
Mario Gabelli 99,725 sh (+1.42%)
|Richard Snow Sold Out|
Jim Simons 36,379 sh (-79.70%)
|Jim Simons 113,769 sh (+212.73%)|
Diamond Hill Capital 454,236 sh (+15.90%)
Paul Tudor Jones 9,324 sh (+11.95%)
|Joel Greenblatt Sold Out|
Chuck Royce 59,300 sh (-1.17%)
Mario Gabelli 98,125 sh (-1.60%)
Arnold Schneider 111,938 sh (-6.71%)
|Paul Tudor Jones 18,323 sh (+96.51%)|
Diamond Hill Capital 527,131 sh (+16.05%)
|Chuck Royce 59,300 sh (unchged)||Mario Gabelli 97,625 sh (-0.51%)|
Arnold Schneider 108,113 sh (-3.42%)
Jim Simons 50,783 sh (-55.36%)
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
OFIX' s 10-Year P/S Range
Min: 0 Max: 0
|Industry:||Medical Devices » Medical Devices|
|Compare:||MDT, SYK, SMA, ZMH, STJ » details|
|Traded in other countries:||OFX.Germany,|
|Orthofix International NV was formed on October 19, 1987 under the laws of the Netherlands Antilles. The Company is a diversified, medical device company engaged in developing and delivering repair and regenerative solutions to the spine and orthopedic markets. Its products are designed to address the lifelong bone-and-joint health needs of patients of all ages, helping them achieve a more active and mobile lifestyle. The Company designs, develops, manufactures, markets and distributes medical devices used mainly by musculoskeletal medical specialists for spine and orthopedic applications. Its main products are spinal implant products human cellular and tissue based products ('HCT/P products') used in surgical procedures, non-invasive regenerative stimulation products used to enhance bone growth and the success rate of spinal fusions and to treat non-union fractures, and external and internal fixation devices used in fracture repair, limb lengthening and bone reconstruction. The Company has administrative and training facilities in the United States, Brazil, the United Kingdom, France, Germany, Puerto Rico and Italy and manufacturing facilities in the U.S. and Italy. The Company directly distributes its products in the U.S., the United Kingdom, Italy, Germany, France, Belgium, Brazil, Australia, and Puerto Rico. The Company manages its business by its four strategic business units (SBUs), which are comprised of BioStim, Biologics, Extremity Fixation, Spine Fixation. The BioStim SBU manufactures, distributes, and provides support services for a portfolio of devices for enhancing bone fusion that utilize the Company's patented pulsed electromagnetic (PEMF) technology. These Food and Drug Administration-approved Class 3 medical devices are indicated as an adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics SBU provides a portfolio of regenerative products that allow physicians to successfully treat various spinal and orthopedic conditions. This SBU specializes in the marketing of the Company's regeneration tissue forms. Biologics distributes its tissues through a network of distributors, sales, representatives and affiliates to market to hospitals, doctors, and other healthcare providers, mainly in the U.S. The Company's partnership with MTF allows it to exclusively market its Trinity Evolution and Trinity Elitetissue forms for musculoskeletal defects to enhance bone fusion. The Extremity Fixation SBU offers products that allow physicians to successfully treat various orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company's orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. The Spine|
|Three Growing Companies Worth a Second Look Oct 09 2013|
|Weekly CEO Buys Highlight: MOSY, PMT, APA, CUBI, OFIX May 26 2013|
|Weekly 3-Year Low Highlights: SBY, PER, OFIX, EDG May 14 2013|
|Orthofix International N.V. Reports Operating Results (10-K) Mar 03 2011|
|Orthofix International N.V. (OFIX) CEO Alan Milinazzo buys 1,100 Shares Nov 09 2010|
|Orthofix International N.V. Reports Operating Results (10-Q) Oct 28 2010|
|Orthofix International N.V. Reports Operating Results (10-Q) Jul 29 2010|
|Orthofix International N.V. Reports Operating Results (10-Q) Apr 29 2010|
|Orthofix International N.V. Reports Operating Results (10-Q) Nov 06 2009|
|Orthofix International Announces Record Revenue in 2nd Quarter 2009 Jul 30 2009|